The Cell and Gene Therapy Catapult (CGT Catapult) is an independent not-for-profit innovation and technology organisation committed to the advancement of cell and gene therapies.
Key information and resources provided on the site include:
Cell and Gene Therapy Catapult (CGT Catapult) Resources
New guidance on the development and marketing of ATMPs in the UK and EU in the post-BREXIT landscape
CGT Catapult's guide on legislative changes regarding the development and marketing of ATMPs in the UK and EU post-BREXIT
Viral vectors: what are the solutions to current scale up challenges?
CGT Catapult's presentation on current state of viral vector manufacturing, barriers, and solutions.
Taking ATMPs to Market
CGT Catapult's presentation on the regulatory framework for ATMPs in the EU, therapy classification, development support and market access pathways
Creating EU market access roadmaps for cell and gene therapies
CGT Catapult's information on market access processes for cell and gene therapies in EU
Additional information and resources developed by CGT Catapult:
- UK Pre-clinical database and commentary
- UK Clinical database and commentary
- National Cell and Gene Therapy Vision for the UK
- a press release is available here.
Czy uważasz informacje na tej stronie za pomocne? Przyślij nam swoje uwagi